DocWire News Editors

DocwireNews

<p>A new analysis published in <a href="https://ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.119.041974"><em>Circulation</em> </a>reveals that many patients with atherosclerotic <a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/walkability-cvd-pollution-and-stroke-and-more/">cardiovascular disease</a> (ASCVD) reported nonadherence due to costs.<p>&ldquo;Medication nonadherence is associated with worse outcomes in patients with ASCVD, a group who requires long-term therapy for secondary prevention,&rdquo; the researchers explained in their study. &ldquo;It is important to understand to what extent drug costs, which are potentially actionable factors, contribute to medication nonadherence.&rdquo;</p><p>The study cohort consisted of a nationally representative survey of US adults who participated in the National Health Interview Survey between 2013 and 2017 (n=14,279). Participants were aged 18 years or older and had a reported history of ASCVD. The researchers determined a participant to have experienced cost-related nonadherence (CRN) if the reported skipping<a href="https://www.docwirenews.com/abstracts/cardiology-abstracts/enhanced-platelet-reactivity-under-aspirin-medication-and-major-adverse-cardiac-and-cerebrovascular-events-in-patients-with-coronary-artery-disease/"> medication</a> doses to save money within the previous 12 months, taking less medication to save money, or delaying filling prescriptions to save money. The authors then employed a survey analysis to obtain national estimates.</p><p>According to the analysis results, a weighted 12.6% (or 2.2 million; 95% CI, 2.1 to 2.4) of the surveyed participants experienced CRN, including 8.6% missing doses (1.5 million), 8.8% taking lower-than-prescribed doses (1.6 million), and 10.5% intentionally delaying filling prescriptions to save money (1.9 million). A number of factors were associated with CRN, including age over 65 years, female sex, low family income, lack of health insurance, and high comorbidity burden. The authors reported that respondents reporting CRN had a 10.8-fold higher odds of requesting low-cost medications and 8.9-fold higher odds of using alternative, nonprescription therapies compared to those who had not reported CRN.</p><p>&ldquo;One in eight patients with ASCVD reports nonadherence to medications because of cost, the researchers wrote. &ldquo;The removal of financial barriers to accessing medications, particularly among vulnerable patient groups, may help improve adherence to essential therapy to reduce ASCVD morbidity and mortality.&rdquo;</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Medication non-adherence due to cost 2013-2017!</p>
<p>AT RISK:</p>
<p>These are people with heart &amp; vascular disease who opt to delay taking, or cut the dose, or skip a dose of their prescribed medications to save money<a href="https://t.co/mXtWAdFc9A">https://t.co/mXtWAdFc9A</a><a href="https://twitter.com/AmerMedicalAssn?ref_src=twsrc%5Etfw">@AmerMedicalAssn</a> <a href="https://twitter.com/CDCDirector?ref_src=twsrc%5Etfw">@CDCDirector</a> <a href="https://twitter.com/ACEPNow?ref_src=twsrc%5Etfw">@ACEPNow</a></p>
<p>&mdash; Elias Said, MD, FACEP (@MdFacep) <a href="https://twitter.com/MdFacep/status/1199321726967898112?ref_src=twsrc%5Etfw">November 26, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Very troubling. <br>Congrats <a href="https://twitter.com/rohan_khera?ref_src=twsrc%5Etfw">@rohan_khera</a> <a href="https://twitter.com/sandeepdasmd?ref_src=twsrc%5Etfw">@sandeepdasmd</a> <a href="https://twitter.com/khurramn1?ref_src=twsrc%5Etfw">@khurramn1</a>! Also, love that this has hit the front page of <a href="https://twitter.com/Reddit?ref_src=twsrc%5Etfw">@reddit</a>! <a href="https://t.co/waiS0dCs9j">https://t.co/waiS0dCs9j</a></p>
<p>&mdash; Nimish Shah, MD (@NNShahMD) <a href="https://twitter.com/NNShahMD/status/1199149462951747586?ref_src=twsrc%5Etfw">November 26, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Creating the evidence for govt. single payer from the usual suspects.  It goes unmentioned that aspirin/statins/anti-hypertensives are available for $4/month. Non-adherence in patients who say they skip because of cost is either poor guidance from docs, or the issues r deeper <a href="https://t.co/bmVYGGGLIl">https://t.co/bmVYGGGLIl</a></p>
<p>&mdash; Anish Koka, MD (@anish_koka) <a href="https://twitter.com/anish_koka/status/1198952669185839104?ref_src=twsrc%5Etfw">November 25, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">This is vastly worrying. There has been a decreasing trend in uninsurance, but <a href="https://twitter.com/hashtag/underinsurance?src=hash&amp;ref_src=twsrc%5Etfw">#underinsurance</a> has been steadily growing. We solved a problem, only to feed/create an equally big one. Amazing to team up with <a href="https://twitter.com/rohan_khera?ref_src=twsrc%5Etfw">@rohan_khera</a> once more!! <a href="https://t.co/i3YKp9ZUa8">https://t.co/i3YKp9ZUa8</a></p>
<p>&mdash; Javier Valero (@jvaleromd) <a href="https://twitter.com/jvaleromd/status/1198934863958687746?ref_src=twsrc%5Etfw">November 25, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">The consequences of unaffordable drug prices in the US published in this week&rsquo;s <a href="https://twitter.com/CircAHA?ref_src=twsrc%5Etfw">@CircAHA</a> protecting <a href="https://twitter.com/hashtag/OurNHS?src=hash&amp;ref_src=twsrc%5Etfw">#OurNHS</a> from free trade deal negotiations should be a national priority <a href="https://twitter.com/hashtag/GE2019?src=hash&amp;ref_src=twsrc%5Etfw">#GE2019</a> <a href="https://twitter.com/drphilhammond?ref_src=twsrc%5Etfw">@drphilhammond</a> <a href="https://twitter.com/mgtmccartney?ref_src=twsrc%5Etfw">@mgtmccartney</a> <a href="https://t.co/bfm0b9ifpg">https://t.co/bfm0b9ifpg</a></p>
<p>&mdash; Nicholas Mills (@HighSTEACS) <a href="https://twitter.com/HighSTEACS/status/1199830102126845952?ref_src=twsrc%5Etfw">November 27, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>&nbsp;</p></p>


Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

One in Eight ASCVD Patients Report Medication Nonadherence Due to Costs

Atherosclerotic Disease

A new analysis published in Circulation reveals that many patients with atherosclerotic cardiovascular disease (ASCVD) reported nonadherence due to costs. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe